In This Article:
Intellia Therapeutics has dosed the first subject in a randomised, placebo-controlled global Phase III trial of its investigational CRISPR-based therapy, NTLA-2002, to treat hereditary angioedema (HAE).
HAELO is a double-blind trial that will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Subjects will be randomised to receive either one 50 mg infusion of the therapy or a placebo. Those in the placebo group will have the option to cross over to the therapy treatment at a 28-week time period.
The trial's key endpoints will measure the count of HAE attacks and the proportion of subjects achieving attack-free status between week five and week 28.
Intellia Therapeutics CEO and president John Leonard said: “We are pleased to have initiated dosing in the HAELO Phase III study as we are in our final lap of clinical development for NTLA-2002. With the promising data we’ve presented thus far, we believe patients could achieve independence from both HAE attacks and medications required to treat this disease.
“We look forward to presenting longer-term data from the ongoing Phase I/II study later this year highlighting the durability of the effect of NTLA-2002.”
Subject enrolment is anticipated to be completed by the second half of this year and the company aims to submit a biologics license application (BLA) in 2026.
The therapy launch in the US market is expected in 2027.
Leveraging CRISPR/Cas9 technology, NTLA-2002 aims to target the kallikrein B1 (KLKB1) gene to eliminate attacks.
NTLA-2002 has received several regulatory designations, including the Food and Drug Administration’s (FDA) orphan drug and Regenerative Medicine Advanced Therapy (RMAT) designation, and the UK Medicines and Healthcare Products Regulatory Agency’s (MHRA) Innovation Passport.
It also secured the European Medicines Agency (EMA)’s PRIME designation, and orphan drug status from the European Commission (EC).
In October last year, the company reported positive outcomes from its ongoing Phase I/II trial of NTLA-2002 for HAE.
"Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.